Clinical Significance of the IL-33-ACOD1-MARCO Axis in HBV-Related Acute-on-Chronic Liver Failure
The IL-33-ACOD1-MARCO Axis in Ameliorating Immune-Mediated Liver Injury and Its Clinical Significance in HBV-Related Acute-on-Chronic Liver Failure
This single-center, prospective observational study will enroll 80 adults: 15 healthy controls, 20 participants with chronic hepatitis B, 20 participants with HBV-related cirrhosis, and 25 participants with HBV-related acute-on-chronic liver failure (HBV-ACLF). The study will not assign any research treatment, and all participants will continue to receive routine clinical care. A 5 mL peripheral blood sample will be collected once from the first three groups. Participants with HBV-ACLF will have 5 mL blood collected at baseline, Day 28, and Day 90, and their 28-day and 90-day survival status will be recorded. Plasma IL-33, IL-6, TNF-alpha, and IL-10 will be measured. Peripheral blood CD14-positive monocytes will be isolated, and ACOD1 and MARCO mRNA expression will be measured by quantitative PCR. The study will compare these markers across groups and assess their relationships with inflammation, disease severity, longitudinal clinical changes, and short-term outcomes.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
HBV-related acute-on-chronic liver failure is characterized by rapid clinical deterioration, systemic inflammation, and high short-term mortality. Previous experimental work in a mouse model of immune-mediated liver injury suggested that IL-33 may induce ACOD1 expression in hepatic macrophages and increase MARCO expression through an itaconate-related pathway, thereby enhancing efferocytosis and reducing inflammatory injury. The complete IL-33-ACOD1-MARCO axis has not been established in patients, and measurements in peripheral blood CD14-positive monocytes cannot be considered direct measurements of liver-resident macrophage function.
This study combines a cross-sectional comparison with longitudinal follow-up. At baseline, plasma IL-33 and inflammatory cytokines and CD14-positive monocyte ACOD1 and MARCO mRNA expression will be compared among healthy controls, participants with chronic hepatitis B, participants with HBV-related cirrhosis, and participants with HBV-ACLF. In the HBV-ACLF group, associations with Model for End-Stage Liver Disease (MELD) score, COSSH-ACLF score, IL-6, TNF-alpha, and IL-10 will be evaluated. Participants with HBV-ACLF will undergo follow-up at Day 28 and Day 90 to assess biomarker changes, all-cause mortality, and liver transplantation status.
Blood will be collected in EDTA-K2 tubes and processed within 2 hours. Plasma IL-33 will be measured by ELISA, and IL-6, TNF-alpha, and IL-10 will be measured by Luminex. Peripheral blood mononuclear cells will be isolated by Ficoll density-gradient centrifugation, followed by CD14-positive magnetic-bead selection and flow-cytometric verification of purity. ACOD1 and MARCO mRNA expression will be measured by quantitative PCR using GAPDH as the reference gene and the 2^-DeltaDeltaCt method.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100015
- : Beijing Ditan Hospital, Capital Medical University
-
Contact:
- Minghui Li, master
- Phone Number: 8613693259096
- Email: wuhm2000@sina.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adults aged 18 to 70 years will be recruited at Beijing Ditan Hospital, Capital Medical University. The study population will include healthy individuals undergoing routine health examinations and patients receiving care at the Liver Disease Center for chronic hepatitis B, HBV-related cirrhosis, or HBV-related acute-on-chronic liver failure. Individuals who meet the applicable group definition and the inclusion and exclusion criteria will be enrolled after providing written informed consent. The planned enrollment is 15 healthy controls, 20 participants with chronic hepatitis B, 20 participants with HBV-related cirrhosis, and 25 participants with HBV-ACLF.
Description
Inclusion Criteria:
- Aged 18 to 70 years, regardless of sex.
- Meets the criteria for one of the following study groups:
Healthy Control Group: No history of liver disease, negative hepatitis B surface antigen (HBsAg), and normal liver function.
Chronic Hepatitis B Group: HBsAg positivity for more than 6 months, no imaging evidence of cirrhosis, and does not meet the diagnostic criteria for HBV-related acute-on-chronic liver failure (HBV-ACLF).
HBV-Related Cirrhosis Group: HBsAg positivity for more than 6 months and cirrhosis confirmed by imaging or pathological examination, without meeting the diagnostic criteria for HBV-ACLF.
HBV-ACLF Group: HBsAg positivity for more than 6 months and meets the COSSH-ACLF diagnostic criteria.
-Fully understands the study and voluntarily provides written informed consent.
Exclusion Criteria:
- Coinfection with hepatitis A, C, D, or E virus, or the presence of another liver disease, including autoimmune liver disease, drug-induced liver injury, or alcohol-related liver disease.
- Confirmed hepatocellular carcinoma.
- Pregnancy or breastfeeding.
- Treatment with immunosuppressive agents or high-dose glucocorticoids within 4 weeks before enrollment.
- Human immunodeficiency virus infection.
- Severe renal impairment, defined as an estimated glomerular filtration rate below 30 mL/min/1.73 m².
- Incomplete key clinical data at enrollment or an anticipated inability to complete the study sampling and follow-up required for the assigned group.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Healthy Control
Adults without a history of liver disease, with negative hepatitis B surface antigen and normal liver function. Participants will undergo one study blood collection at enrollment. |
|
Chronic Hepatitis B
Adults with hepatitis B surface antigen positivity for more than 6 months, without imaging evidence of cirrhosis and not meeting the COSSH-ACLF diagnostic criteria. Participants will undergo one baseline study blood collection. |
|
HBV-Related Cirrhosis
Adults with chronic HBV infection and cirrhosis confirmed by imaging or pathology, without meeting the COSSH-ACLF diagnostic criteria. Participants will undergo one baseline study blood collection. |
|
HBV-Related Acute-on-Chronic Liver Failure
Adults with hepatitis B surface antigen positivity for more than 6 months who meet the COSSH-ACLF diagnostic criteria. Participants will undergo study blood collection at baseline, Day 28, and Day 90 and will be followed for 28-day and 90-day survival outcomes. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma IL-33 Concentration at Baseline Across Study Groups
Time Frame: Baseline (at enrollment or hospital admission)
|
Plasma IL-33 concentration will be measured in EDTA plasma by enzyme-linked immunosorbent assay (ELISA) in healthy controls, participants with chronic hepatitis B, participants with HBV-related cirrhosis, and participants with HBV-related acute-on-chronic liver failure. |
Baseline (at enrollment or hospital admission)
|
|
ACOD1 mRNA Expression in Peripheral Blood CD14-Positive Monocytes at Baseline Across Study Groups
Time Frame: Baseline (at enrollment or hospital admission)
|
Peripheral blood mononuclear cells will be isolated and CD14-positive monocytes will be selected using magnetic beads. ACOD1 mRNA expression will be measured by quantitative PCR, with GAPDH as the reference gene, and reported as relative expression calculated using the 2^-DeltaDeltaCt method. |
Baseline (at enrollment or hospital admission)
|
|
MARCO mRNA Expression in Peripheral Blood CD14-Positive Monocytes at Baseline Across Study Groups
Time Frame: Baseline (at enrollment or hospital admission)
|
Peripheral blood mononuclear cells will be isolated and CD14-positive monocytes will be selected using magnetic beads. MARCO mRNA expression will be measured by quantitative PCR, with GAPDH as the reference gene, and reported as relative expression calculated using the 2^-DeltaDeltaCt method. |
Baseline (at enrollment or hospital admission)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation of Plasma IL-33 With ACOD1 and MARCO mRNA Expression in Participants With HBV-ACLF
Time Frame: Baseline
|
At baseline in participants with HBV-related acute-on-chronic liver failure, Spearman correlation coefficients will be calculated between plasma IL-33 concentration and ACOD1 and MARCO mRNA relative expression in peripheral blood CD14-positive monocytes. |
Baseline
|
|
Association of ACOD1 and MARCO mRNA Expression With Disease Severity and Inflammatory Markers in Participants With HBV-ACLF
Time Frame: Baseline
|
At baseline in participants with HBV-related acute-on-chronic liver failure, correlations of ACOD1 and MARCO mRNA relative expression with Model for End-Stage Liver Disease (MELD) score, COSSH-ACLF score, plasma IL-6, TNF-alpha, and IL-10 will be assessed. |
Baseline
|
|
28-Day All-Cause Mortality in Participants With HBV-ACLF
Time Frame: From baseline through Day 28
|
Vital status and date of death will be determined from medical records and, when necessary, telephone follow-up. Liver transplantation will be recorded separately and will not be counted as death. |
From baseline through Day 28
|
|
90-Day All-Cause Mortality in Participants With HBV-ACLF
Time Frame: From baseline through Day 90
|
Vital status and date of death will be determined from medical records and, when necessary, telephone follow-up. Liver transplantation will be recorded separately and will not be counted as death. |
From baseline through Day 90
|
|
Change in Plasma IL-33 Concentration in Participants With HBV-ACLF
Time Frame: Baseline, Day 28, and Day 90
|
Plasma IL-33 concentration will be measured by ELISA at baseline, Day 28, and Day 90. Within-participant changes over time will be described and analyzed using repeated-measures methods specified in the protocol. |
Baseline, Day 28, and Day 90
|
|
Change in ACOD1 mRNA Expression in Peripheral Blood CD14-Positive Monocytes in Participants With HBV-ACLF
Time Frame: Baseline, Day 28, and Day 90
|
ACOD1 mRNA relative expression in peripheral blood CD14-positive monocytes will be measured by quantitative PCR at baseline, Day 28, and Day 90, using GAPDH as the reference gene and the 2^-DeltaDeltaCt method. |
Baseline, Day 28, and Day 90
|
|
Change in MARCO mRNA Expression in Peripheral Blood CD14-Positive Monocytes in Participants With HBV-ACLF
Time Frame: Baseline, Day 28, and Day 90
|
MARCO mRNA relative expression in peripheral blood CD14-positive monocytes will be measured by quantitative PCR at baseline, Day 28, and Day 90, using GAPDH as the reference gene and the 2^-DeltaDeltaCt method. |
Baseline, Day 28, and Day 90
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Infections
- Virus Diseases
- Digestive System Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Communicable Diseases
- DNA Virus Infections
- Hepadnaviridae Infections
- Hepatitis, Chronic
- Hepatitis
- Pathological Conditions, Signs and Symptoms
- Hepatitis B
- Hepatitis B, Chronic
Other Study ID Numbers
Other Study ID Numbers
- ZZLX2026052
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.